| Previous close | 389.48 |
| Open | 389.48 |
| Bid | 388.60 |
| Ask | 390.80 |
| Strike | 400.00 |
| Expiry date | 2024-07-19 |
| Day's range | 389.48 - 389.48 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
Yahoo FinanceNovo Nordisk sales up 26% driven by GLP-1s, misses 11% on Wegovy
Novo Nordisk CEO Lars Jørgensen tells Yahoo Finance the company is confident about a robust GLP-1 sales year despite missing Wall Street estimates.
ZacksEarnings Season: 3 Companies Boosting Guidance
Earnings season continues to chug along, with results from many companies already delivered. And concerning positivity, all three of these companies' report fit the criteria, lifting outlooks following the results.
Barrons.comNovo Nordisk’s Wegovy Sales More Than Doubled. Why the Stock Is Falling.
The Danish pharmaceutical firm, Europe’s most valuable company, said sales of the weight-loss drug jumped 106% in the first quarter.
© 2024 Yahoo. All rights reserved.